Zydus Cadila Drug
-
{
- All
- News
- Videos
-
Zydus Cadila Gets US Approval To Market Generic Schizophrenia Drug
Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market generic drug Cariprazine capsules, which are used in the treatment of schizophrenia.
-
Zydus Cadila Gets Final Approval From US FDA For Pre-Surgery Injection
India-based pharma giant, Zydus Cadila received final approval from US Food and Drug Administration (FDA) for Glycopyrrolate injection that is used before surgery to decrease the volume of secretions from the mouth, lungs and stomach.
-
India To Buy 1 Crore Zydus Cadila 'Needle-Free' Covid Shots At Rs 265 Each
The indigenously developed world's first DNA-based needle-free COVID-19 vaccine ZyCoV-D received emergency use authorisation from the drug regulator on August 20.
-
Biological E Gets Drug Regulator's Approval For Phase 2nd, 3rd Trial On Children
The permission has been given to Biological E after the recommendation from the Subject Expert Committee.
-
"3 Doses, 66 Per Cent Efficacy": 5 Things To Know About Zydus Cadila's Covid Vaccine For Children
Zydus Cadila's Covid vaccine ZyCoV-D, meant for adults and children aged 12 years and above, was today approved for "restricted use in emergency situation" by the Central Drugs Standard Control Organisation (CDSCO).
-
1st Covid Vaccine For Children Above 12 Approved In India
India's drug regulator on Friday approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country.
-
Drug Regulator Examining Zydus Cadila's Covid Vaccine For Children: Dr VK Paul
Drugs Controller General of India (DCGI) is examining pharmaceutical major Zydus Cadila's COVID-19 vaccine for children, said Dr VK Paul, Member-Health, Niti Aayog on Friday.
-
India's Zydus Cadila Seeks Nod For Its Covid Vaccine ZyCoV-D
Indian drugmaker Zydus Cadila said on Thursday it has applied to the country's drug regulator for emergency use approval of its COVID-19 vaccine and that it plans to manufacture up to 120 million doses of the shot annually.
-
Zydus Cadila May Seek Emergency Use Approval For Vaccine Next Week: Report
Indian pharmaceutical major Zydus Cadila is likely to apply to the central drugs regulator seeking emergency use authorisation for its COVID-19 vaccine ZyCoV-D next week, official sources said on Friday.
-
Zydus Cadila's "Virafin" Approved For Treating Moderate Covid Cases
The Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, "Virafin" for treating moderate COVID-19 infection in adults.
-
Zydus Cadila Gets Nod For Phase 3 Trials Of Its Covid Vaccine Candidate
The Drugs Controller General of India (DCGI) has approved conducting phase III trials of the country's first DNA vaccine candidate against COVID-19 being developed by Zydus Cadila, the Department of Biotechnology said on Sunday.
-
Zydus Cadila Covid Therapy "PegiHep" Gets Nod For Phase 3 Clinical Trial
Drug firm Zydus Cadila said today that it has received the approval from the Drugs Controller General of India (DCGI) to start phase 3 clinical trials with its biological therapy PegiHep in COVID-19 patients.
-
Zydus Cadila Launches "Most Affordable" COVID-19 Drug Remdesivir In India
Drug firm Zydus Cadila on Thursday said it has launched Remdesivir under the brand name Remdac, used to treat patients suffering from severe symptoms of COVID-19, in the Indian market.
-
Human Trials Of Second COVID-19 Vaccine Candidate Begin
Indian pharmaceutical giant Zydus Cadila has initiated the phase 1, 2 clinical trial to evaluate the safety and immunogenicity of coronavirus vaccine candidate by intradermal (injection) route in 1,048 subjects after the pharma company got approval from Drugs Controller General of India (DCGI) earlier this month.
-
Second COVID-19 Vaccine Cleared For Phase I, II Human Trials In India
The Drug Controller General of India has approved pharmaceutical firm Zydus Cadila to start Phase I and Phase II human clinical trials of its COVID-19 vaccine. This is the second vaccine after Hyderabad-based Bharat Biotech's COVAXIN to get the approval.
-
Zydus Cadila Gets US Approval To Market Generic Schizophrenia Drug
Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market generic drug Cariprazine capsules, which are used in the treatment of schizophrenia.
-
Zydus Cadila Gets Final Approval From US FDA For Pre-Surgery Injection
India-based pharma giant, Zydus Cadila received final approval from US Food and Drug Administration (FDA) for Glycopyrrolate injection that is used before surgery to decrease the volume of secretions from the mouth, lungs and stomach.
-
India To Buy 1 Crore Zydus Cadila 'Needle-Free' Covid Shots At Rs 265 Each
The indigenously developed world's first DNA-based needle-free COVID-19 vaccine ZyCoV-D received emergency use authorisation from the drug regulator on August 20.
-
Biological E Gets Drug Regulator's Approval For Phase 2nd, 3rd Trial On Children
The permission has been given to Biological E after the recommendation from the Subject Expert Committee.
-
"3 Doses, 66 Per Cent Efficacy": 5 Things To Know About Zydus Cadila's Covid Vaccine For Children
Zydus Cadila's Covid vaccine ZyCoV-D, meant for adults and children aged 12 years and above, was today approved for "restricted use in emergency situation" by the Central Drugs Standard Control Organisation (CDSCO).
-
1st Covid Vaccine For Children Above 12 Approved In India
India's drug regulator on Friday approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country.
-
Drug Regulator Examining Zydus Cadila's Covid Vaccine For Children: Dr VK Paul
Drugs Controller General of India (DCGI) is examining pharmaceutical major Zydus Cadila's COVID-19 vaccine for children, said Dr VK Paul, Member-Health, Niti Aayog on Friday.
-
India's Zydus Cadila Seeks Nod For Its Covid Vaccine ZyCoV-D
Indian drugmaker Zydus Cadila said on Thursday it has applied to the country's drug regulator for emergency use approval of its COVID-19 vaccine and that it plans to manufacture up to 120 million doses of the shot annually.
-
Zydus Cadila May Seek Emergency Use Approval For Vaccine Next Week: Report
Indian pharmaceutical major Zydus Cadila is likely to apply to the central drugs regulator seeking emergency use authorisation for its COVID-19 vaccine ZyCoV-D next week, official sources said on Friday.
-
Zydus Cadila's "Virafin" Approved For Treating Moderate Covid Cases
The Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, "Virafin" for treating moderate COVID-19 infection in adults.
-
Zydus Cadila Gets Nod For Phase 3 Trials Of Its Covid Vaccine Candidate
The Drugs Controller General of India (DCGI) has approved conducting phase III trials of the country's first DNA vaccine candidate against COVID-19 being developed by Zydus Cadila, the Department of Biotechnology said on Sunday.
-
Zydus Cadila Covid Therapy "PegiHep" Gets Nod For Phase 3 Clinical Trial
Drug firm Zydus Cadila said today that it has received the approval from the Drugs Controller General of India (DCGI) to start phase 3 clinical trials with its biological therapy PegiHep in COVID-19 patients.
-
Zydus Cadila Launches "Most Affordable" COVID-19 Drug Remdesivir In India
Drug firm Zydus Cadila on Thursday said it has launched Remdesivir under the brand name Remdac, used to treat patients suffering from severe symptoms of COVID-19, in the Indian market.
-
Human Trials Of Second COVID-19 Vaccine Candidate Begin
Indian pharmaceutical giant Zydus Cadila has initiated the phase 1, 2 clinical trial to evaluate the safety and immunogenicity of coronavirus vaccine candidate by intradermal (injection) route in 1,048 subjects after the pharma company got approval from Drugs Controller General of India (DCGI) earlier this month.
-
Second COVID-19 Vaccine Cleared For Phase I, II Human Trials In India
The Drug Controller General of India has approved pharmaceutical firm Zydus Cadila to start Phase I and Phase II human clinical trials of its COVID-19 vaccine. This is the second vaccine after Hyderabad-based Bharat Biotech's COVAXIN to get the approval.
